| # | Drug | Count |
|---|---|---|
| 0 | FULVESTRANT | 35 |
| 1 | LETROZOLE | 33 |
| 2 | LETROZOLE TABLETS | 29 |
| 3 | BEVACIZUMAB | 28 |
| 4 | OCTREOTIDE ACETATE | 27 |
| 5 | NIVOLUMAB | 22 |
| 6 | RIBOCICLIB | 21 |
| 7 | TRAMETINIB | 21 |
| 8 | EVEROLIMUS | 20 |
| 9 | TACROLIMUS | 20 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NALDEMEDINE | 5 | 0.0030 |
| 1 | FLURANDRENOLIDE | 1 | 0.0030 |
| 2 | ZOLBETUXIMAB | 3 | 0.0020 |
| 3 | LEVOLEUCOVORIN INJECTION | 5 | 0.0016 |
| 4 | LEVOLEUCOVORIN | 6 | 0.0016 |
| 5 | BEVACIZUMAB-BVZR | 1 | 0.0014 |
| 6 | BARICITINIB | 4 | 0.0013 |
| 7 | FULVESTRANT | 35 | 0.0010 |
| 8 | CEFPODOXIME PROXETIL | 1 | 0.0010 |
| 9 | TOPOTECAN | 6 | 0.0010 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 3 | 0.0020 |
| 1 | Estrogen Receptor Antagonist [EPC] | 35 | 0.0009 |
| 2 | Provitamin D2 Compound [EPC] | 15 | 0.0005 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 10 | 0.0005 |
| 4 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | 1 | 0.0004 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 36 | 0.0004 |
| 6 | Aromatase Inhibitor [EPC] | 41 | 0.0004 |
| 7 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 7 | 0.0003 |
| 8 | Somatostatin Analog [EPC] | 2 | 0.0003 |
| 9 | Epidermal Growth Factor Receptor Antagonist [EPC] | 13 | 0.0003 |